<DOC>
	<DOC>NCT00681967</DOC>
	<brief_summary>To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa</brief_summary>
	<brief_title>Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Written informed consent Age over 18 years Histologically proven squamous cell cancer of the head &amp; neck (SCCHN) Indication for postoperative Radiotherapy: pT3, pT4, pN2b, pN2c, pN3 Hypersensitivity to ZD1839 or any of the excipients of this product Tumour stage M1 Coexisting malignancies diagnosed within the last 5 years. Exceptions: basal cell carcinoma, cervical cancer in situ Absolute neutrophil counts &lt;1.5 x 109</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>squamous cell cancer of the head &amp; neck</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>IRESSA</keyword>
	<keyword>EGFR Inhibitor</keyword>
	<keyword>EGFR-tyrosine kinase inhibitor</keyword>
	<keyword>Subjects with histologically proven squamous cell cancer of the head &amp; neck</keyword>
	<keyword>Cohort 1:qualifying for postoperative radiotherapy</keyword>
	<keyword>(pT3, pT4, pN2b, pN2c, pN3).</keyword>
	<keyword>Cohort 2:qualifying for definite chemoradiotherapy</keyword>
	<keyword>(Lateral oropharynx, tonsils: T1N2b-3, T2N1-3, T3any N;</keyword>
	<keyword>Base of tongue, vallecula: T1N1-3, T2-4 any N; Oral cavity,</keyword>
	<keyword>glottic and supraglottic larynx; Any TN1-3, T3-4 any N;</keyword>
	<keyword>Hypopharynx: T1N1-3, T2-4 and N)</keyword>
</DOC>